轻松健康(02661)于2025年12月15日至12月18日招股，该公司拟全球发售2654万股，其中香港发售占 10%，国际发售占90%，另有15%超额配股权，每股发售价22.68港元。每手200股，预期股份将于2025 年12月23日在联交所开始买卖。 公司提供健康相关及保险相关解决方案。根据沙利文报告的资料，按2024年的收入计，公司于中国数字 综合健康服务及健康保险服务市场排名第10位。公司致力于通过一套易用、精准且可负担的健康解决方 案，为有需要的人提供保障和支持。 公司为寻求全面健康解决方案的用户提供健康相关服务，包括早期疾病筛查相关推广及咨询、健康检查 及咨询、医疗预约服务以及保健品销售。作为公司服务的重要组成部分，公司亦赋能行业参与者以数字 营销的形式策划优质科普内容，并推广健康相关公共举措。为了资助用户的健康支出，并满足其保障需 求，公司亦通过公司的互联网保险平台保险相关服务，为用户提供方便地获取各种健康保险产品的机 会。公司的综合平台提供健康服务和保险资金资源，能够满足用户的整体健康需求。 集团与广东横琴粤澳深度合作区澳琴合鸣投资合伙企业(有限合伙)("澳琴合鸣")订立基石投资协议，据 此， ...

轻松健康2025年12月15日至12月18日招股，拟全球发售2654万股，其中香港发售占10%，国际发售占 90%，另有15%超额配股权，每股发售价22.68港元。预期股份将于2025年12月23日在联交所开始买卖。 公司提供健康相关及保险相关解决方案。根据沙利文报告，按2024年收入计，公司在中国数字综合健康 服务及健康保险服务市场排名第10位。公司为用户提供早期疾病筛查推广及咨询、健康检查及咨询、医 疗预约服务以及保健品销售等健康相关服务，同时通过互联网保险平台为用户提供健康保险产品机会。 集团与广东横琴粤澳深度合作区澳琴合鸣投资合伙企业(有限合伙)订立基石投资协议，澳琴合鸣按发售 价认购或促使其指定实体认购合共约人民币1亿元可购入的有关数目的发售股份。 假设超额配股权未获行使，全球发售所得款项净额将约为5.134亿港元。集团拟将全球发售所得款项净 额用于以下用途：约40.0%用于提升集团的品牌知名度、提高用户参与度及加强与业务合作伙伴的合 作；约20.0%用于医学研究和真实世界研究；约20.0%用于提升集团在AI及大数据领域的技术能力，以 便更广泛应用于集团的产品及服务；约10.0%用于拓展至更多地区及 ...

公司为寻求全面健康解决方案的用户提供健康相关服务，包括早期疾病筛查相关推广及咨询、健康检查 及咨询、医疗预约服务以及保健品销售。作为公司服务的重要组成部分，公司亦赋能行业参与者以数字 营销的形式策划优质科普内容，并推广健康相关公共举措。为了资助用户的健康支出，并满足其保障需 求，公司亦通过公司的互联网保险平台保险相关服务，为用户提供方便地获取各种健康保险产品的机 会。公司的综合平台提供健康服务和保险资金资源，能够满足用户的整体健康需求。 按发售价为每股发售股份22.68港元计算(假设超额配股权未获行使)，全球发售所得款项净额将约为 5.134亿港元。集团拟将全球发售所得款项净额用于以下用途：约40.0%将用于提升集团的品牌知名度、 提高用户参与度及加强与业务合作伙伴的合作;约20.0%将用于医学研究和真实世界研究;约20.0%将用于 提升集团在AI及大数据领域的技术能力，以便更广泛应用于集团的产品及服务;约10.0%将用于拓展至更 多地区及海外市场;及约10.0%用作营运资金及其他一般公司用途。 智通财经APP讯，轻松健康(02661)于2025年12月15日至12月18日招股，该公司拟全球发售2654万股， ...

Core Viewpoint - The leading health technology platform, Qingsong Health Group, has officially passed the hearing for its IPO on the Hong Kong Stock Exchange, aiming to enhance its digital health services and insurance solutions through advanced technology [1][2] Group 1: Company Overview - Qingsong Health Group was established in 2014 and is recognized as a leading digital comprehensive health service and health insurance solution platform in China [1] - According to a report by Sullivan, Qingsong Health Group ranks seventh in China's digital health service market based on projected revenue for 2024 [1] Group 2: Service Offerings - The company provides a diverse range of personalized health services, including insurance products, health screenings, health consultations, medical appointment services, and health product sales, targeting users seeking comprehensive health solutions [1] - Qingsong Health Group leverages AI and other technologies to empower industry participants in creating high-quality health education content [1] Group 3: Technological Development - The company has developed its own AI technology stack, AIcare, which integrates artificial intelligence, big data, and cloud computing capabilities, applied across various business segments such as user services, intelligent risk control, personalized marketing, product innovation, and operational efficiency [1] - Through the continuous optimization of AIcare, Qingsong Health Group has achieved a deep and precise transformation of its health and insurance businesses, setting a new benchmark for "AI + Health" in the industry [1] Group 4: IPO Fund Utilization - The funds raised from the IPO are intended for ongoing research and development, strengthening AI technology infrastructure, expanding the digital health ecosystem, enhancing user experience, and pursuing international expansion to accelerate the realization of the long-term strategic goal of "technology empowering public health" [2]

Core Viewpoint - The company, Easy Health Group, is updating its prospectus for an IPO on the Hong Kong Stock Exchange, with CICC and China Merchants Securities International as joint sponsors [1]. Company Overview - Easy Health Group is a one-stop platform in China focusing on providing digital integrated health services and health insurance solutions. It ranks 10th in the digital integrated health services and health insurance market in China based on projected 2024 revenue [4]. - The company aims to offer accessible, precise, and affordable health solutions to individuals in need, including screening promotion, health checks, medical appointment services, and health product sales [4]. Service Offerings - The company provides a variety of personalized health services targeting users seeking comprehensive health solutions, including screening promotion and consultation services, integrated health service packages, digital marketing (health education), and digital medical research support [4][5][6][7][8]. - Digital marketing services were launched in 2023, offering tailored digital marketing solutions to pharmaceutical companies and charitable foundations, with a significant increase in the number of clients and health education content produced over the years [5]. - The company supports the pharmaceutical industry by providing comprehensive solutions for medical research, including real-world study design and clinical trial data analysis, with a growing number of clients [6]. Financial Performance - The company reported revenues of approximately RMB 490 million in 2023, RMB 945 million in 2024, and projected RMB 656 million for the first half of 2025. The profits for the same periods were RMB 73.62 million, RMB 10.39 million, and RMB 86.05 million respectively [9][10]. - The revenue cost and gross profit margins have shown fluctuations, with gross profit margins of 82.6% in 2022, decreasing to 32.5% by 2025 [10].